The trial evaluated Verzenios®? (abemaciclib) in combination with fulvestrant for the treatment of women with HR+, HER2- metastatic breast cancer who progressed following endocrine therapy. The results demonstrated that Verzenios led to a statistically significant improvement in OS, a very important milestone for patients who are fighting MBC.
1 Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib plus Fulvestrant
on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast
Cancer that Progressed on Endocrine Therapy–MONARCH 2. JAMA Oncol.
Copyright©2019 Eli Lilly and Company. Lilly® and Verzenios® (abemaciclib) are registered trademarks of Eli Lilly and Company. All rights reserved.